MedTrace Logo

oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection

NCT05938296 · Status: SUSPENDED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2025-11-19

No results posted yet for this study

Summary

This study will be a Phase 1, multi-center, open-label, dose escalation followed by the recommended phase 2 dose (RP2D) expansion study to characterize safety, tolerability, biodistribution, virus shedding and preliminary efficacy of intratumoral injection of BS006 in patients with advanced solid tumors.

Conditions

Interventions

DRUG

BS006 Injection

BS006 will be given every two weeks, and up to 4mL in each treatment. There will be three dose levels: 1×10\^6 CCID50/mL, 5×10\^6 CCID50/mL, 1×10\^7 CCID50/mL.

Sponsors & Collaborators

  • Binhui Biopharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-19
Primary Completion
2026-12-19
Completion
2026-12-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05938296 on ClinicalTrials.gov